Ameriprise
TRDA icon

Ameriprise’s Entrada Therapeutics TRDA Stock Holding History

Ameriprise’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Buy
70,395
+115
+0.2% +$1.1K ﹤0.01% 3650
2026
Q1 		$887K Sell
70,280
-14,613
-17% -$167K ﹤0.01% 3354
2025
Q4 		$873K Buy
84,893
+14,967
+21% +$126K ﹤0.01% 3399
2025
Q3 		$406K Buy
69,926
+24,980
+56% +$146K ﹤0.01% 3698
2025
Q2 		$302K Buy
44,946
+3,923
+10% +$31.6K ﹤0.01% 3695
2025
Q1 		$371K Buy
41,023
+399
+1% +$4.97K ﹤0.01% 3606
2024
Q4 		$702K Buy
40,624
+2,517
+7% +$45.6K ﹤0.01% 3400
2024
Q3 		$609K Buy
38,107
+24,560
+181% +$387K ﹤0.01% 3418
2024
Q2 		$193K Buy
+13,547
New +$193K ﹤0.01% 3697

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5AM Venture Management
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Merck & Co
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MPM BioImpact
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
StepStone Group
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Ameriprise's TRDA Position: Q2 2026 in Review

Ameriprise increased its Entrada Therapeutics (TRDA) stake by 0.16% in Q2 2026, buying an estimated $1.1K and bringing the position to 70,395 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

Ameriprise first reported a position in TRDA in Q2 2024 and has held it in 9 quarters since. The position peaked at $887K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Ameriprise held 70,395 shares of Entrada Therapeutics worth $518K as of Q2 2026.
  • Ameriprise bought 115 Entrada Therapeutics shares in Q2 2026, an estimated $1.1K.
  • Entrada Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3650 holding.
  • Ameriprise first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Ameriprise's Entrada Therapeutics position peaked at $887K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.